Tag: FWB:6BX

October 9, 2019

Relevium Enters Into Manufacturing Agreement With Bio V Pharma and Registers 400 NPN Numbers With Health Canada

Relevium is pleased to announce today that it has registered 400 Natural Product Numbers with Health Canada through its main...
September 23, 2019

Relevium CEO: We’re Positioned to Lead Latin America’s Cannabis Industry

Relevium CEO Aurelio Useche joined the Investing News Network to provide an overview of the company and an update on...
September 19, 2019

Relevium Announces Intention to Spin-Out Pediatric Cannabis Subsidiary Biocannabix

Relevium Technologies Inc. announces its intention to create a new, publicly-traded company through a spin-out of Biocannabix Health Corporation.
August 14, 2019

Why Cannabis Health Products are Gaining Momentum

Thanks to the health benefits of cannabinoids like CBD and THC, consumers are beginning to see cannabis health and wellness...
August 1, 2019

Relevium Announces Record Sales From the Bioganix® Brand and Provides CBD Update

Relevium Technologies Inc. (TSXV:RLV, OTCQB:RLLVF, Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that the company hit a record high...
July 10, 2019

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients
June 27, 2019

Leveraging Cannabinoids in Pediatric Medicine

Research-based evidence has shown potential for health improvements from the use of medical cannabinoids in pediatric medicine.